JavierMunozMDMS, FACP

Hematology • Phoenix, AZ

Hematologic Oncology

Director, Lymphoma Program at Mayo Clinic.

Join to view full profile

Dr. Munoz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Munoz's full profile

Already have an account?

Office
5777 E. Mayo Boulevard
Phoenix, AZ 85050
Is this information wrong?

Summary

Dr. Munoz specializes in treating lymphomas and he is the Director of the Lymphoma Program at Mayo Clinic in Arizona. He is certified in Hematology and Medical Oncology. Dr. Munoz studied medicine in the “Universidad Peruana Cayetano Heredia” in Lima, Peru. Subsequently, he completed his residency and fellowship in Hematology-Oncology at Henry Ford Hospital in Michigan. Dr. Munoz also completed a Master of Science in patient-based research and an Investigational Cancer Therapeutics fellowship at the University of Texas MD Anderson Cancer Center in Houston before relocating to Arizona. Dr. Munoz also obtained an executive MBA in healthcare leadership and management for physicians from the University of Texas. He has been principal investigator in multiple cutting-edge lymphoma trials including immunotherapy and CAR T-cells. Within Mayo Clinic, Dr. Munoz is the Chair of the Feasibility Committee at a 3-site enterprise level, and the Associate Director of the Cancer Center Clinical Trials Office in Arizona. Dr. Munoz has published in internationally renowned journals including the New England Journal of Medicine, Nature Reviews, Blood, and JAMA. Dr. Munoz's personal goal is the development of non-chemotherapy agents, via novel clinical trials, to serve patients suffering with cancer.

ASH Choosing Wisely® Champions - Javier Munoz, MD

Javier Munoz, MD, of Banner MD Anderson Cancer Center in Gilbert, Arizona, was selected as one of the three inaugural ASH Choosing Wisely Champions

Movimiento en la búsqueda de una alternativa contra el cáncer

Investigaciones buscan una alternativa para tratar el cáncer, que incluso podría erradicarlo. Primer Impacto: Encuentra las noticias y reportajes más impactante

Why Watch and Wait Is Necessary

Why is the watch-and-wait period necessary for many people with chronic lymphocytic leukemia (CLL)? Dr. Javier Munoz, from Banner MD Anderson Cancer Center, exp

Education & Training

Henry Ford HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
Henry Ford HospitalResidency, Internal Medicine, 2005 - 2008
Cayetano Heredia UniversityClass of 2004
University of Texas M D Anderson Cancer CenterFellowship, Investigational Cancer Therapeutics Fellowship In Early Drug Development

Certifications & Licensure

AZ State Medical License 2012 - 2025
TX State Medical License 2011 - 2017
MI State Medical License 2005 - 2011
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

ASH Hematology Opportunities for the Next-generation of Research Scientists HONORS Award (Mentor) American Society of Hematology, 2019
Health Volunteers Overseas (HVO) American Society of Hematology, 2018
ASCO Virtual Mentoring Program American Society of Clinical Oncology, 2018
ASH Minority Resident Hematology Award Program (Mentor) American Society of Hematology, 2018
ASCO Diversity Mentoring American Society of Clinical Oncology, 2017
ASH Practice Partnership American Society of Hematology, 2017
40 under 40 Phoenix Business Journal, 2017
Choosing wisely champion American Society of Hematology, 2016
ASH Advocacy Leadership Institute American Society of Hematology, 2015
Join now to see all

Clinical Trials

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas Start of enrollment: 2012 Nov 19
Completed
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Start of enrollment: 2013 Jun 13
Completed
Phase 1, Phase 2
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2013 Nov 29
Completed
Phase 1, Phase 2
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL Start of enrollment: 2013 Aug 30
Completed
Phase 1, Phase 2
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
Completed
Phase 1, Phase 2
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Start of enrollment: 2014 Sep 04
Completed
Phase 1, Phase 2
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Start of enrollment: 2015 Apr 21
Completed
Phase 1, Phase 2
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas Start of enrollment: 2016 Dec 01
Recruiting
Phase 2
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) Start of enrollment: 2015 Nov 09
Completed
Phase 2
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2016 May 11
Completed
Phase 1, Phase 2
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2016 Aug 01
Completed
Phase 1
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product Start of enrollment: 2016 Oct 01
Terminated
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) Start of enrollment: 2017 Mar 02
Completed
Phase 2
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Start of enrollment: 2017 Feb 28
Completed
Phase 2
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Start of enrollment: 2017 Feb 15
Completed
Phase 1
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Start of enrollment: 2017 Jun 20
Active, not recruiting
Phase 2
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Start of enrollment: 2017 Oct 04
Terminated
Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Active, not recruiting
Phase 1, Phase 2
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2018 Jan 25
Active, not recruiting
Phase 3
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) Start of enrollment: 2018 Jul 27
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) Start of enrollment: 2018 Oct 17
Recruiting
Phase 1, Phase 2
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2019 Mar 08
Completed
Phase 1, Phase 2
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Start of enrollment: 2018 Oct 15
Completed
Phase 1
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma Start of enrollment: 2019 Jan 29
Completed
Phase 2
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma Start of enrollment: 2019 May 01
Active, not recruiting
Phase 1
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma Start of enrollment: 2019 Nov 05
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Kai Rejeski, Yucai Wang, Doris K Hansen, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Müller, Wolfgang Bethge, Javier Munoz, Razan Mohty, Veit ...> ;Blood Advances. 2024 Apr 23
3 citations
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
Michael D Jain, Miriam T Jacobs, Feng Gao, Loretta J Nastoupil, Jay Y Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwo...> ;Blood Advances. 2024 Feb 27
Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
Ghobadi, A., Munoz, J., Westin, J., Locke, F., Miklos, D., Rapoport, A., Perales, M., Reagan, P., McGuirk, J., Jacobson, C., Kersten, M., Avivi, I., Peng, A., Schupp, ...> ;Blood Advances. 2024 Feb 5
Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL.
Javier Munoz, Anagha Deshpande, Lisa Rimsza, Grzegorz S Nowakowski, Razelle Kurzrock> ;Cancer Treatment Reviews. 2024 Mar 1
Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
Omran Saifi, Scott C Lester, William G Breen, William G Rule, Yi Lin, N Nora Bennani, Allison Rosenthal, Javier Munoz, Hemant S Murthy, Mohamed A Kharfan-Dabaja, Jenni...> ;American Journal of Hematology. 2024 Jan 1
Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review.
Fortin Ensign, S., Huff, D., Ryan, M., Palmer, J., Munoz, J.> ;Journal of Immunotherapy and Precision Oncology. 2023 Nov 1
Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20B Cell Lymphoma.
Ian W Flinn, Jessica Sachs, Benjamin Exter, Ann Ranger, Patricia Harris, Francis Payumo, Rajneesh Nath, Mehdi Hamadani, Jason R Westin, Veronika Bachanova, Munoz, J., ...> ;Transplantation and Cellular Therapy. 2024 Feb 1
Facial Nerve Palsy After Chimeric Antigen Receptor T-Cell Therapy.
Alexis B Richards, Geoffrey P Fletcher, Javier L Munoz> ;Mayo Clinic Proceedings. 2023 Oct 1
Allogeneic hematopoietic stem cell transplantation in adults with dendritic/histiocytic neoplasms.
Charles Gaulin, Fiona Craig, Shannon Fortin Ensign, Ryan Robetorye, Sarah Gibson, Katalin Kelemen, Nandita Khera, Jose Leis, Mazie Tsang, Allison Rosenthal, Javier Mun...> ;Leukemia & Lymphoma. 2023 Dec 1
3 citations
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene aut...
Kai Rejeski, Yucai Wang, Omar Albanyan, Javier Munoz, Pierre Sesques, Gloria Iacoboni, Lucia Lopez-Corral, Isabelle Ries, Veit L Bücklein, Razan Mohty, Martin Dreyling...> ;American Journal of Hematology. 2023 Nov 1
3 citations
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, Philippe Armand, Tae Min Kim, Dok Hyun Yoon, Amitkumar Mehta, Richard Greil, Jason Westin, Izidore S Lossos, Javie...> ;Blood Advances. 2023 Oct 24
1 citations
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma.
Omran Saifi, William G Breen, Scott C Lester, William G Rule, Bradley J Stish, Allison Rosenthal, Javier Munoz, Yi Lin, Radhika Bansal, Matthew A Hathcock, Patrick B J...> ;Haematologica. 2023 Nov 1
48 citations
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abh...> ;Blood. 2023 May 11
4 citations
Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy.
Bezerra, E., Iqbal, M., Munoz, J., Khurana, A., Wang, Y., Maurer, M., Bansal, R., Hathcock, M., Bennani, N., Murthy, H., Rosenthal, A., Paludo, J., Villasboas, J., Joh...> ;Blood Advances. 2023 Apr 25
8 citations
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Marc S Hoffmann, Bradley D Hunter, Patrick W Cobb, Juan C Varela, Javier Munoz> ;Transplantation and Cellular Therapy. 2023 Jul 1
6 citations
Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia.
Constantine Tam, Javier Munoz, Gavin Cull, Stephen Opat, Heather Allewelt, Xiaoping Zhang, Jennifer C Stern, James Hilger, Kunthel By, Aileen Cohen, Alessandra Tedeschi> ;Hemasphere. 2023 Apr 1
Glabellar mass in a case of mantle-cell lymphoma treated by CAR T-cell therapy.
Javier Munoz, Michael Wang> ;Lancet. 2023 Mar 25
3 citations
Clinical advances in epigenetic therapies for lymphoma.
Allison C Rosenthal, Javier L Munoz, J C Villasboas> ;Clinical Epigenetics. 2023 Mar 4
34 citations
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Yucai Wang, Preetesh Jain, Frederick L Locke, Matthew J Maurer, Matthew J Frank, Javier L Munoz, Saurabh Dahiya, Amer M Beitinjaneh, Miriam T Jacobs, Joseph P Mcguirk,...> ;Journal of Clinical Oncology. 2023 May 10
Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver.
Javier Munoz, Katalin Kelemen, Vrushali Dabak, Amr Hanbali, Razelle Kurzrock, Anagha Deshpande> ;Journal of Immunotherapy and Precision Oncology. 2023 Feb 1
8 citations
The iRregimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, ...> ;Eclinicalmedicine. 2023 Feb 1
6 citations
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.
Omran Saifi, William G Breen, Scott C Lester, William G Rule, Bradley J Stish, Allison Rosenthal, Javier Munoz, Yi Lin, Radhika Bansal, Matthew A Hathcock, N Nora Benn...> ;International Journal of Radiation Oncology, Biology, Physics. 2023 Aug 1
Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy.
Shannon P Fortin Ensign, Charles Gaulin, Maya Hrachova, Michael Ruff, Ehab Harahsheh, Kevin Vicenti, Januario Castro, Javier Munoz, Allison Rosenthal, Maciej M Mrugala> ;Current Treatment Options in Oncology. 2022 Dec 1
3 citations
Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective.
Ginna Granroth, Allison Rosenthal, Maggie McCallen, Christopher Coughlin, Hollie Benson, Jeanne Palmer, Januario E Castro, Javier Munoz> ;Current Oncology Reports. 2022 Dec 1
9 citations
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
Javier L Munoz, Yucai Wang, Preetesh Jain, Michael Wang> ;Current Oncology Reports. 2022 Oct 1
Join now to see all

Abstracts/Posters

Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
LBA-6 Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Z...
Sattva S. Neelapu, MD1, Frederick L. Locke, MD2, Nancy L. Bartlett, MD3, Lazaros Lekakis, MD4*, David Miklos, MD, PhD5, Caron A. Jacobson, MD6, Ira Braunschweig, MD7, ..., ASH - Late-Breaking Abstracts Session, San Diego USA, 12/6/2016
A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Ce...
Andre Goy, MD1, Radhakrishnan Ramchandren, MD2*, Nilanjan Ghosh, MD, PhD3, Javier Munoz, MD4, David S. Morgan, MD5, Nam H. Dang, MD, PhD6, Mark Knapp, MD7, Maria Delio..., ASH - Results from Prospective Clinical Trials, San Diego USA, 12/4/2016
Join now to see all

Lectures

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Reduction of Post-Treatment Scanning Using EMR Alerts
ASH San Diego 2016 - The ASH Choosing Wisely® Campaign: 2016 ASH Choosing Wisely Champions - 12/5/2016

Authored Content

CAR-T Cell Therapy Updates from TCT 2021February 2021

Press Mentions

Match Day Profile: Julie Tran and Diep NguyenMarch 18th, 2022
$Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)$
Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)November 3rd, 2020
Incidence and Clinical Presentation of MCLJanuary 30th, 2020
Join now to see all